Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma

Autor:	J. Jouppila, Juhani Vilpo, E. Järvenpää, M. Kááriáinen, C. Wasastjerna, Heikki Hallman, Allan Rajamäki, A. Hänninen, G. Järventie, D. Nyman, Erkki Elonen, J. Savola, I. P. Palva, S. Pakkala, Tapani Ruutu, K. Soininen, B. Isomaa, T-T. Pelliniemi, P. Nyländen, E. Koivunen, T. Oivanen, H. Mäkelä, K. Kätkä, Reino Lahtinen, T. Pulli, M. Lehtinen, A. Laitinen, A. Almqvist, Tuomo Timonen, H. Kilpi, K. Ala Harja, P. Ahrenberg, M. Ilvonen
Rok vydání:	2009
Předmět:	medicine.medical_specialty Vincristine Chemotherapy business.industry medicine.medical_treatment Combination chemotherapy Hematology General Medicine Gastroenterology Surgery Methylprednisolone Internal medicine Prednisolone medicine Doxorubicin business Dexamethasone medicine.drug Epirubicin
Zdroj:	European Journal of Haematology. 44:121-124
ISSN:	1600-0609 0902-4441
DOI:	10.1111/j.1600-0609.1990.tb00362.x
Popis:	94 patients with refractory multiple myeloma were treated in a multicentre trial with combinations of cytotoxic drugs including anthracyclines. All were refractory to a 5-drug combination containing 3 alkylating agents, vincristine and methylprednisolone (MOCCA). With a combination of epirubicin and iphosphamide a 50% response was achieved in 9% of 22 patients. The response rate after schedule VAP (vincristine, doxorubicin and prednisolone) was 8% of 13 patients and that after schedule VAD (vincristine, doxorubicin and dexamethasone) 20% of 59 patients. The previous chemotherapy had lasted for less than 12 months in 13 cases from among all these patients, and 5 of these (38%) responded. In contrast, there were only 10 responders (12%) among the 81 patients with longer previous chemotherapy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c6c38882c057c4fbd001103386004e76 https://doi.org/10.1111/j.1600-0609.1990.tb00362.x Zobrazit plný text záznamu Plný text